SSY Group Wins NMPA Approval for Sodium Glycerophosphate Injection

SSY Group ( (HK:2005) ) has provided an announcement.

SSY Group Limited has received approval from China’s National Medical Products Administration to produce and register its Sodium Glycerophosphate Injection (10ml:2.16g), classified as a type 4 chemical drug and deemed to have passed consistency evaluation, making it the third such approval among PRC entities. The newly approved nutritional injection, used as a phosphorus supplement in adult parenteral nutrition and for patients with phosphorus deficiency, strengthens SSY Group’s injectable nutrition portfolio and may enhance its competitive position in China’s hospital drug market by expanding its range of clinically important supportive therapies.

The most recent analyst rating on (HK:2005) stock is a Buy with a HK$3.50 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.

More about SSY Group

SSY Group Limited is a pharmaceutical group based in China, focused on the research, development and production of injectable drugs and related medical products, with a portfolio that includes nutritional and parenteral therapies serving hospitals and healthcare institutions.

YTD Price Performance: -13.50%

Average Trading Volume: 7,659,198

Technical Sentiment Signal: Sell

Current Market Cap: HK$8.68B

See more data about 2005 stock on TipRanks’ Stock Analysis page.